An obesity medicine physician writes that weight-loss drugs such as Ozempic have been getting a bad rap, almost as if those ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

A charity boss who struggled for years to shed pounds despite having undergone surgery has hailed weight-loss jabs as ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...